Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients
Phase 4
Completed
- Conditions
- PneumopathyMajor Abdominal SurgeryAcute PancreatitisNeurological Diseases
- Registration Number
- NCT00560157
- Lead Sponsor
- Société des Produits Nestlé (SPN)
- Brief Summary
Comparison of metabolic and nutritional effects of an enteral immune enhancing diet with those of a standard polymeric one, in ICU patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- 18<age<89, ASA score<4 , SAPS II score>10
- requiring the administration of an exclusive tube feeding nutrition during 7 days and beginning at the latest in the three days following the aggression
- ICU patients hospitalized for:
- neurologic affections
- pneumopathy
- major abdominal surgery or serious acute pancreatitis
- written informed consent
Exclusion Criteria
- pregnancy or breast feeding
- immunosuppressive therapy
- radiotherapy or chemotherapy in the last six month
- uncontrolled septic choc
- auto-immune disease
- hepatic,renal or digestive insufficiency
- hyperlipidemia
- diabetes mellitus type 1
- digestive malabsorption
- life threatening situation
- treatments with growing hormone, glutamine or its metabolites or precursors such as ornithine alpha keto glutarate
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Variation of Glutamine after 90 min of enteral product administration J5
- Secondary Outcome Measures
Name Time Method Nutritional parameters, immunologic parameters, functionality renal, Biological marker of oxidative stress J1, J5, J8 Tolerance Daily until J8
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie immune enhancement by enteral nutrition in ICU patients with acute pancreatitis?
How does Crucial enteral feeding compare to standard polymeric diets in managing ICU-induced metabolic stress?
Which biomarkers correlate with improved outcomes in ICU patients receiving immune-modulating enteral nutrition?
What adverse events are associated with immune-enhancing enteral diets in post-abdominal surgery ICU patients?
Are there combination therapies with Crucial enteral nutrition for neurological disease-related ICU complications?
Trial Locations
- Locations (2)
Hopital A. BECLERE
🇫🇷Clamart, France
Hopital Saint Antoine
🇫🇷Paris, France
Hopital A. BECLERE🇫🇷Clamart, France